Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC

Launched by SHANGHAI CHEST HOSPITAL · Aug 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a type of lung surgery called sleeve lobectomy, which is done to remove lung cancer after patients have received treatments like chemotherapy or immunotherapy to shrink the tumor beforehand. The study aims to compare two ways of doing this surgery: a less invasive method using small cameras and instruments (called minimally invasive surgery) versus the traditional open surgery where a larger cut is made in the chest. Researchers want to see which approach leads to better outcomes during and after surgery, including how well the cancer is removed and how long patients live without the cancer coming back.

Adults diagnosed with a specific type of lung cancer (non-small cell lung cancer) who have already had these initial treatments and are scheduled for sleeve lobectomy may be eligible to participate. To join, patients need to have complete medical records and agree to follow-up visits for at least a year. This study is important because it looks at how modern surgical techniques work alongside newer cancer treatments, which could help doctors choose the safest and most effective surgery for future patients. Participants won’t receive new treatments as part of the study; instead, their medical information from their surgery and recovery will be carefully reviewed to learn more about what works best.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Histologically confirmed NSCLC
• • Undergoing sleeve lobectomy with curative intent
• • Receipt of neoadjuvant therapy (chemotherapy, immunotherapy, target therapy, etc.)
• • Surgical approach: either minimally invasive (VATS or RATS) or open thoracotomy
• • Availability of complete perioperative and follow-up data (minimum 12-month follow-up or until death)
• • Signed informative consent
• Exclusion Criteria:
• • Sublobar resections (e.g., segmentectomy) or pneumonectomy
• • Absence of neoadjuvant therapy
• • Purely diagnostic surgical procedures
• • Incomplete medical records or lost to follow-up
• • Metastatic (stage IV) disease at time of surgery